A NEW GENERATION OF IMMUNOTHERAPIES

In August 2021, AyuVis published the paper "Chitin-Derived AVR-48 Prevents Experimental Bronchopulmonary Dysplasia (BPD) and BPD-Associated Pulmonary Hypertension in Newborn Mice" in the International Journal of Molecular Science, a peer-reviewed scientific journal with online access published by MDPI. The paper was written in collaboration with Dr. Pragnya Das and Dr. Vineet Bhandari at Drexel University and Cooper Health Hospital, respectively.  

​

Read the paper on our Publications webpage.

In June 2021, AyuVis' Founder and CEO was interviewed by Margaret Murray, an Analyst at DeciBio Consulting. This interview is part of a series on the DeciBio Blog which spotlights women in leadership positions. Dr. Acharya and Margaret have an engaging discussion on Dr. Acharya's professional development and experience and her passion for saving lives.

​

Read the full interview here.

​

In February 2021, AyuVis was granted Rare Pediatric Drug Designation from the U.S. Food and Drug Administration (FDA) for our small molecule drug AVR-48 for the prevention of bronchopulmonary dysplasia (BPD) in at-risk preterm infants. The RPDD and ODD open the opportunity for AyuVis to apply for FDA-funded grants once we have an open IND application. The RPDD additionally opens the opportunity to apply for a Priority Review Voucher at the time we file our New Drug Application.

“The FDA granting the Rare Pediatric Disease Drug Designation to our lead candidate for BPD is highly encouraging to our team and a strong step forward toward developing the first FDA-approved therapy for BPD,” said David Riley, MD, MBA, a board-certified neonatologist and AyuVis’ Chief Medical Officer.

​

View the full press release here.

​

In January 2021, AyuVis was granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for our small molecule drug AVR-48 for the prevention of bronchopulmonary dysplasia (BPD). This recognition by the FDA is validation of our science and great motivation to our extraordinarily talented scientific, clinical and business team to march toward our goal -- to the clinic and beyond.​

​

View the full press release here.

In November 2020, AyuVis' Founder and CEO, Dr. Suchismita Acharya was nominated and then selected for a Rising Star Award by Bio North Texas' iC3 Summit committee. Five (5) awardees were selected from a large competitive group of nominees based on who the committee believed embodies the growing pulse of innovation in the life sciences and healthcare arena in North Texas. AyuVis is grateful for this important recognition, and to share the stage with a group of stellar winners. As part of the award, Dr. Acharya was interviewed, and the video was shown on the live event feed during the iC3 Summit. See the video here: 

In October 2020, AyuVis' Founder and CEO, Dr. Suchismita Acharya, and CBO, Keith Bryant attended the Virtual Bio Investor Forum. This event brought together biotech startups with a variety of investors, from large VCs to family offices. 

In September 2020, AyuVis team members participated in another Digital RESI conference. Our Founder and CEO, Dr. Suchismita Acharya, CBO, Keith Bryant, and Business Advisor, Ranjan Misra, met with several investors to engage discussions on our open Series A equity financing round. It was a productive conference resulting in ongoing follow-up discussions with several pharmaceutical companies, VCs, and family offices. 

AyuVis participated in the virtual Venture Dallas pitch event during September 15 through October 18, 2020, which was held on the Thumbraise app.  We uploaded a video of our Founder & CEO, Dr. Suchismita Acharya, presenting our elevator pitch supported with additional information. You can view the elevator pitch here:

​

​

​

​

​

In June 2020, AyuVis participated in a 3-day Digital RESI Conference. Suchi Acharya, Founder and CEO, Rusty Bromley, Director of Operations, and Ranjan Misra, Business Advisor, met with several different VCs, family offices, pharma companies, and angel groups to discuss the open Series A round.

AyuVis was invited to apply for the RESI Innovation Challenge.  RESI selected 37 applicants for the challenge and attendees voted for the most innovative. AyuVis won second place and RESI sent out an email newsletter announcing the winners which will reach 37,000+ people, with the link to our Innovation Challenge webpage. On this webpage is a video presentation by AyuVis’ new CMO, Dr. David Riley, reviewing information on an AyuVis RESI poster with other supporting documents. The webpage will be active for one month following the conference. Congrats to the AyuVis team!

In January 2020, Ayuvis' second patent was published.

​

See the patent here.

In January 2020, Dallas Innovates published an article written by Jeff Bounds, which recognized the number of Alcon alumni that have become entrepreneurs or involved with life science startups in the DFW area following their careers with Alcon. Our Founder and CEO, Dr. Suchismita Acharya, was quoted in this article for AyuVis Research, Inc. The article highlights how Dr. Acharya’s experience working for Alcon as a medicinal chemist and project leader in a preclinical research group prepared her for starting her own start-up pharmaceutical company.

​

Read the article here.

In November 2019, our Founder and CEO, Dr. Suchismita Acharya, was selected as one of the eight panelists for TechFW’s Global Entrepreneurship Week “Connect the Dots” event. As a part of this panel, Dr. Acharya had the opportunity to share her personal and professional experiences of conducting business globally. She represented AyuVis well and engaged the audience with stories of business spanning across countries and cultures.  

In October 2019, the AyuVis team attended the Texas-Israel Alliance Healthcare Conference at UT Southwestern in Dallas, TX. The attendees from AyuVis included Dr. Suchismita Acharya, CEO, Ranjan Misra, Business Adviser, Dr. Stella Robertson, Drug Development Adviser, and Sarah Spain, Operations Associate. This conference included a full day of speakers and panels, discussing a variety of topics from raising capital as a life science startup in Texas, to collaboration between Israel and Texas for R&D, and big data in healthcare. It was a learning experience for the AyuVis team.

In September 2019, AyuVis’ Rusty Bromley, COO, and Dwight Horton, CFO, attended the RESI Conference in Boston, MA. They met with a variety of potential investors discussing the upcoming Equity Round of fundraising. This was a prosperous event that allowed for meaningful relationships to be initiated, and further discussions are ongoing.

In June 2019, AyuVis Research traveled to Washington D.C. to engage in a face-to-face Pre-Investigational New Drug (IND) meeting with the FDA. In this meeting, preclinical data was presented to the FDA for their review. The discussion then continued about further preclinical studies AyuVis has planned and additional preclinical studies that would support a strengthened IND application. The agency made several helpful recommendations regarding preclinical testing under Good Laboratory Practices (GLP).

​

The results of these discussions were very positive, as we learned we will be able to file our IND application and start the human clinical trials sooner than originally planned. After receiving the FDA’s written comments in July, and reviewing them with our Scientific Advisory Board, we are developing detailed plans to move forward.

The 2019 American Thoracic Society (ATS) Conference took place in Dallas, TX this past May. This is the largest international research conference in the respiratory area with over 14,000 attendees this year. AyuVis was excited for the opportunity to attend and engage with thoracic industry leaders. We hosted a booth in the exhibition hall and encouraged attendees to fill out a brief survey to support our market research. We also interacted with several pharmaceutical companies in this space, providing us contacts for further discussion on possible strategic partnerships.

​

Dr. Suchismita Acharya, AyuVis Founder and CEO, and a key collaborator with AyuVis, Dr. Vineet Bhandari, and his team from Drexel University presented and discussed a poster on AyuVis’ lead compound for Bronchopulmonary Dysplasia. The poster discussion was well attended and increased the awareness of the research at AyuVis among the scientific community.

In late Feburary of this year, AyuVis published the paper "Novel Chitohexaose Analog Protects Young and Aged mice from CLP Induced Polymicrobial Sepsis"  in Nature Scientific Reports, which is a peer reviewed journal with online access.  It is part of the Nature Research group and has a robust peer-review process.  

​

Read the paper here.

Publishing this article was a strategic business and scientific goal.  It puts AyuVis on the map and helps validate what we are doing.  We are really pleased to have published a detailed full science paper on our first compound, AVR25, explaining the mechanism of action of this novel class of compounds and the exciting original sepsis efficacy data, around which the company was first formed.  The authors are the major labs who have partnered with us at Drexel University, University of Cincinnati, Brown, Wash University in St Louis, and the University North Texas Health Science Center's Preclinical Service Center, where the company has lab space.  

In January 2019, AyuVis' COO, Rusty Bromley, and Business Advisor, Ranjan Misra, attended the Biotech Showcase Conference taking place January 7th through 9th at the Hilton San Francisco Union Square in San Francisco, CA. Biotech Showcase provides a platform where companies can showcase their innovative assets and spark relationships with potential investors and strategic partners. This conference is one of the industry’s leading investor conferences expecting more than 3,500 attendees, 2,200 companies, and over 1,000 investors.

AyuVis requested and was selected to present at the conference, which assists in drawing the attention of investors for one-on-one meetings. AyuVis was subsequently selected by Proactive Investors, a financial media portal, for a video interview which can be viewed here . This interview was then distributed by the publisher through major financial channels and syndicated to 10 global financial portals in 4 languages which attract 11M+ site visitors per year.

Redefining Early Stage Investments (RESI) Conference

September 6th, 2018

​

The Fall Redefining Early Stage Investments (RESI) Conference was held September 6th, 2018 at the Boston Marriott Copley Place, Boston, MA

​

AyuVis was one of the thirty companies selected for the Innovation Challenge to showcase the company and products in the exhibit hall and gain more visibility from the early stage investors in attendance.  These companies were selected from all the global early-stage companies across Biotech, Medtech, Diagnostics & Digital Health that were attending the RESI Conference.

​

AyuVis published a poster titled:

Drug Development for Bronchopulmonary Dysplasia an Orphan Pediatric Disease

​

Author: Dr. Suchi Acharya in collaboration with Dr. Vineet Bhandari, Dr. Kurt Albertine, and Dr. Beamon Agarwal

The poster was presented by Dr. Acharya and Dr. Agarwal and generated excellent discussions about the lead and back-up compounds that have been developed, and the promising results from the pre-clinical tests.  Treating preterm mice pups with the compounds showed marked improvement in lung development without affecting other organs.  Treating BPD is a priority of the NIH due to the high cost of treatment and the current unmet need.  The current treatment options have potential long term complications and costs for continued treatment.

53rd Annual ACLPS Meeting
May 31st to June 2nd, 2018

​

ACLPS 2018, the 53rd annual meeting of the Academy of Clinical Laboratory Physicians and Scientists (ACLPS), was held May 31 – June 2, 2018, at the Houston Methodist Hospital and Research Institute, Houston, Texas. 

​

AyuVis was invited to present our scientific work on intra-abdominal infection and sepsis (cIAI) at the ACLPS Annual meeting.  The poster title was:

​

Novel Chitohexaose Compounds to Treat Abdominal Peritonitis Leading to Sepsis

Authors:  Dr. Beamon Agarwal, Dr. Pragnya Das, Dr. Santosh Panda, and Dr. Suchismita Acharya

​

The poster was presented by Dr. Beamon Agarwal and Dr. Suchi Acharya.  The presentation attracted a large crowd that was keen to learn more about the progress we had made in developing a lead and several backup compounds, and favorable results achieved during the pre-clinical testing. This generated quite a bit of further discussion about the findings and results.  The unique three pronged approach of immunomodulation, anti-inflammatory, and anti-microbial action positions the AyuVis compounds as a new class of drugs to treat cIAI.

​

For additional information, please contact Dr. Suchi Acharya at sacharya@ayuvis.com or Dr. Beamon Agarwal at bagarwal@ayuvis.com

The I-Corps™ program is designed to support training that will help project teams at NIH- and CDC-funded small businesses overcome key obstacles along the path of innovation and commercialization.

Dr. Suchi Acharya, CEO, AyuVis Research did an invited oral presentation on the preclinical results of the small molecule technology for treating complicated intra-abdominal infection that leads to sepsis at the 5th Annual Congress on Bacteriology and Infectious Disease conference in Chicago during May 2017.

AyuVis Research has been selected as one of the 17 participants in I-Corps at NIH program. the I-Corps at NIH curriculum is designed to provide scientists from NIH SBIR funded companies with real-world, hands-on entrepreneurship training, facilitated by domain experts from the biotech sector. This program seeks to accelerate the development and commercialization of new products and services.AyuVis is expecting to gain immense experience to develop it's commercialization strategy for its proprietary small molecule technology for treating sepsis, and difficult to treat septic wounds. The program outcome along with Phase-I SBIR data will enable the team for a successful Phase-II SBIR from NIH/DOD and attract investors for angel/crowd funding.

AyuVis Research has been awarded a Phase-I Small Business Innovative Research (SBIR) grant funding from National Institute of Allergy and Infectious Diseases (NIAID) in January 2017 to conduct the preclinical proof of concept study of company’s proprietary multi functional small molecule for sepsis, septicemia.